Piper Jaffray Cuts Arena Pharma (ARNA) to Neutral, Price Target Slashed to $1.50

September 17, 2010 8:20 AM EDT
Get Alerts ARNA Hot Sheet
Price: $1.37 +0.74%

Rating Summary:
    5 Buy, 10 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ARNA Now!
Join SI Premium – FREE
An analyst at Piper Jaffray has downgraded shares of Arena Pharma (Nasdaq: ARNA) this morning following yesterday's news that an FDA panel has failed to recommend approval of its lorcaserin and the subsequent resumption of trading last night.

The stock is indicated to open today's session down more than 45% at around $2.

Piper's rating on Arena moves from Overweight to Neutral. The firm also slashed its price target on the stock all the way from $10 to $1.50.

As analysts will likely be all over Arena shares today, stay tuned to our Analyst Ratings page to track all the market-moving calls.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Downgrades, Trader Talk

Related Entities

Piper Jaffray

Add Your Comment